



(12) Translation of
European patent specification

(11) NO/EP 3371165 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/12 (2006.01)
A61K 31/506 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.06.20
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.01.26
(86)	European Application Nr.	16804956.7
(86)	European Filing Date	2016.11.04
(87)	The European Application's Publication Date	2018.09.12
(30)	Priority	2015.11.04, US, 201562250575 P 2016.02.17, US, 201662296143 P 2016.05.25, US, 201662341189 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Merck Patent GmbH, Frankfurter Strasse 250, 64293 Darmstadt, Tyskland
(72)	Inventor	HUCK, Bayard R., Im Gartenfeld 24A, 61440 Oberursel, Tyskland GOODSTAL, Samantha M., 100 Main Campus Drive Apt.12213, Lexington, Massachusetts 02421, USA GIMMI-MCKIM, Claude, Schmittenhoehle 5, 4313 Moehlin, Sveits
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	A BTK INHIBITOR FOR USE IN TREATING CANCER
(56)	References Cited:	WO-A2-2012/170976

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP3371165

1

Patentkrav

- 5 **1.** 1-(4-(((6-amino-5-(4-fenoksyfenyl)pyrimidin-4-yl)amino)metyl)-4-fluoropiperidin-1-yl)prop-2-en-1-on (A225) og farmasøytisk anvendelige salter, inkludert blandinger derav i alle forhold, for anvendelse i behandling eller forebygging av myeloproliferative lidelser eller kreft, hvori kreften er valgt fra Non-Hodgkins lymfom kappecellelymfom og Non-Hodgkins lymfom diffust storcellet b-celle-lymfom, inkludert abc-undertype.
- 10 **2.** Forbindelsen for anvendelse ifølge krav 1 og farmasøytisk anvendelige salter derav, inkludert blandinger derav i alle forhold, hvori forbindelsen anvendes i en farmasøytisk sammensetning sammen med en farmasøytisk akseptabel bærer.